The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
March 7th 2024
The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
Improving Access to Treatment Remains a Challenge in AML, Says Dr Jeffrey Lancet
June 9th 2023Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Watch
Experts Spar Over Role of Real-World Data as Replacement for Clinical Trials in Hematology
June 9th 2023A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged the limitations and current challenges with these data.
Read More
Florida Cancer Specialists Highlights Role in Development of Polatuzumab Vedotin Plus R-CHP in DLBCL
May 10th 2023Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.
Read More
China Approves Zanubrutinib in Treatment-Naïve CLL/SLL and Waldenström Macroglobulinemia
May 9th 2023China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.
Read More
Dr Jeffrey Lancet Discusses the Evolving Therapy Landscape of AML
May 4th 2023Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.
Watch
NCCN Session Offers Considerations for Frontline, Second-line Treatment Choices in CLL
April 12th 2023An April 1 session at the 2023 National Comprehensive Cancer Network (NCCN) on updates in CLL/SLL featured results on the ALPINE study, which led to the January 2023 approval of zanubrutinib in the frontline setting.
Read More
Even Oncologists Sold on Value-Based Care Hesitate to Embrace the EOM
March 10th 2023Members of the Association of Community Cancer Centers (ACCC) Alternative Payment Coalition discussed strategies for succeeding in value-based care and voiced concerns surrounding the upcoming Enhancing Oncology Model (EOM) during a panel discussion at the ACCC 2023 Annual Meeting and Business Summit.
Read More
Study Shows Survival Disparities Among Children With ALL Living in US-Mexico Border Regions
March 4th 2023Children with acute lymphoblastic leukemia living in US-Mexico border regions had worse 5-year survival rates compared with children living in other parts of Texas, a recent study found.
Read More
While treatment with allogeneic hematopoietic cell transplantation (allo-HCT) showed improved disease-free survival compared with conventional consolidation chemotherapy, the findings suggest there may not be an overall survival (OS) benefit with allo-HCT for patients with intermediate-risk acute myeloid leukemia (AML) during first complete remission.
Read More